Anggaya, Riley .
HRN: 25-65-73 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/29/2025
OXACILLIN 500MG (VIAL)
01/29/2025
02/04/2025
IV
300mg
Q6h
Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes